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Mutations in Cu,Zn superoxide dismutase (SOD1) are associated with amyotrophic lateral sclerosis (ALS).
Among more than 100 ALS-associated SOD1 mutations, premature termination codon (PTC) mutations exclu-
sively occur in exon 5, the last exon of SOD1. The molecular basis of ALS-associated toxicity of the mutant
SOD1 is not fully understood. Here, we show that nonsense-mediated mRNA decay (NMD) underlies clear-
ance of mutant mRNA with a PTC in the non-terminal exons. To further deﬁne the crucial ALS-associated
SOD1 fragments, we designed and tested an exon-fusion approach using an artiﬁcial transgene SOD1
T116X
that harbors a PTC in exon 4. We found that the SOD1
T116X transgene with a fused exon could escape
NMD in cellular models. We generated a transgenic mouse model that overexpresses SOD1
T116X.T h i s
mouse model developed ALS-like phenotype and pathology. Thus, our data have demonstrated that a
‘mini-SOD1’ of only 115 amino acids is sufﬁcient to cause ALS. This is the smallest ALS-causing SOD1 mol-
ecule currently deﬁned. This proof of principle result suggests that the exon-fusion approach may have
potential not only to further deﬁne a shorter ALS-associated SOD1 fragment, thus providing a molecular
target for designing rational therapy, but also to dissect toxicities of other proteins encoded by genes of mul-
tiple exons through a ‘gain of function’ mechanism.
INTRODUCTION
Mutations in the Cu, Zn-superoxide dismutase gene (SOD1)
are associated with 20% of familial amyotrophic lateral scler-
osis (ALS) cases (1,2). Transgenic mice overexpressing
ALS-associated SOD1 mutants develop ALS-like disease,
but transgenic mice overexpressing human wild-type SOD1
(hwtSOD1) or SOD1-deﬁcient mice remain free of ALS-like
phenotype, suggesting that mutant SOD1 causes the disease
through the gain of a toxic property (3,4). We recently demon-
strated that the conversion of mutant SOD1 from a soluble
form to insoluble aggregates by crosslinking through intermo-
lecular disulﬁde bonds via oxidation of cysteine residues in
SOD1 is associated with ALS-like phenotype in transgenic
mouse models, leading to a hypothesis that oxidation-
mediated SOD1 aggregates underlie such a toxic property of
mutant SOD1 (5,6). Further support for this hypothesis came
from the observations that wild-type SOD1 could also be
recruited into the insoluble aggregates by intermolecular
crosslinking and this recruitment correlated with exacerbation
of the disease or conversion to a disease phenotype (5,6). Two
out of four cysteine residues in SOD1 are preferentially
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Cys-146 (5,6). The preferential involvement of individual
cysteines in SOD1 during the aggregate formation suggests
that the amino acid sequences ﬂanking cysteines and the con-
formation of SOD1 protein play a crucial role in determination
of the crosslinking reactivity between cysteines during SOD1
aggregation upon oxidation.
Human SOD1 is relatively a small gene with ﬁve exons in
approximately an 11 kb genomic DNA fragment. Thus far
.100 mutations, widely distributed in the SOD1 polypeptide
and involving .70 of its 153 codons, have been identiﬁed in
ALS. Most of the mutations result in substitution of amino
acids. Nine mutations leading to premature termination
codons (PTCs) in the last exon (exon 5), resulting in deletions
of the C-terminus of SOD1, have been reported in ALS
patients (www.alsod.org). No PTC in any exon other than
exon 5 has been identiﬁed in ALS patients to date. Trans-
genic mice overexpressing some of the PTC mutations in
the last exon developed an ALS-like phenotype, suggesting
that an N-terminus polypeptide of 125 amino acids has sufﬁ-
cient toxicity to cause the motor neuron degeneration in
mouse models (7).
Some types of human genetic diseases, including some
neurodegenerative diseases, are caused by genetic mutations
through a ‘gain of function’ mechanism. Understanding of
the pathogenic mechanisms of these diseases is currently a
major challenge. Previous studies have demonstrated that a
full length mutant protein may not be an essential require-
ment for the development of disease, but the disease-
associated toxicities may only lie in a crucial fragment of
the protein. It is well established that amyloid-beta peptides
(Abeta), as short as 40 to 42 amino acid derived from
amyloid precursor protein of 695 amino acid, are the main
constituents of amyloid plaques which are thought to be
causal for the memory loss and cognitive decline in
Alzheimer’s disease (8). Similarly, a prion protein fragment
of 106 amino acid out of the full length of 254 amino acid
sufﬁciently supports pathogenic PrP
sc formation in transgenic
mice (9). In mutant SOD1-mediated ALS, it has been proven
that a C-terminal-truncated SOD1 protein of 125 amino acid
out of a full length of 153 amino acid is sufﬁcient to cause an
ALS-like phenotype in transgenic mice (7). To further deﬁne
smaller pathogenic fragments or protein domains may not
only add to the understanding of the pathogenic mechanisms,
but also facilitate minimization of the therapeutic targets
(10), thus facilitating the design of rational therapies
(11,12).
In the present study, we attempted to further deﬁne the
ALS-associated toxicity of SOD1 by overexpressing shorter
SOD1 polypeptides in transgenic mouse models. We encoun-
tered a technical challenge due to nonsense-mediated mRNA
decay (NMD) mechanism. Therefore, we designed and
tested an exon-fusion approach using an artiﬁcial transgene
with a PTC at codon 116 in exon 4 of the human SOD1
gene (hSOD1
T116X). Our data suggested that this approach
may have powerful potentials for molecular dissection of the
disease-associated toxicities of SOD1 and other proteins
encoded by genes with multiple exons, thus to facilitate under-
standing the molecular basis of pathogenic mechanisms and
designing therapeutic strategies.
RESULTS
NMD underlying clearance of mutant mRNA with
premature stop codons of SOD1
Nine PTC mutations in SOD1 have been reported in ALS
patients. All of these PTCs exclusively occur in exon 5, the
last exon of SOD1. No PTC mutation in any exon other than
exon 5 has currently been reported, raising a possibility that
a full-length polypeptide encoded by the ﬁrst four exons
may be required for the ALS-associated toxicity. In transgenic
mice overexpressing some of the ALS-associated PTC
mutants, it has been demonstrated that an N-terminal SOD1
polypeptide of 125 amino acid has sufﬁcient ALS-associated
toxicity (5,13–15). To understand the pathogenic mechanism
of ALS and to further deﬁne crucial ALS-associated fragments
of SOD1, we constructed two artiﬁcial transgenes using the
human SOD1 gene as a template. The transgene hSOD1
E77X
has a PTC at codon 77 in exon 3; while the transgene
hSOD1
K91X has a PTC at codon 91 in exon 4. Multiple
copies of these transgenes were detected in the transgenic
mice (Fig. 1A). However, SOD1 mRNA was barely detected
(Fig. 1B), and these transgenic mice remained free of
ALS-like phenotype in their life time. The obviously lower
mRNA expression in multiple lines of these transgenic mice,
when compared to our previous SOD1 transgenic mice harbor-
ing non-PTC mutations, suggests that mRNA transcribed from
hSOD1
E77X and hSOD1K91X transgenes was degraded
(Fig. 1B). To test if the mRNA degradation was due to
NMD, we ﬁrst analyzed the transgene hSOD1
E77X in cell
culture models. Both hwtSOD1 and hSOD1
E77X transgenes
were co-transfected at the same molar ratio into NIH/3T3
cells that were derived from a mouse embryonic ﬁbroblast
cell line. Resulting mRNA was reverse-transcribed to cDNA.
Human transgene-derived SOD1 cDNA, but not mouse
endogenous SOD1 cDNA, was PCR-ampliﬁed using human-
speciﬁc SOD1 primers. The PCR product was sequenced.
Dosage analysis was carried out based on the ratios of the
peak height [mutant (T)/wt (G)] (refer to Materials and
Methods) (Fig.1C and D). We found that the steady-state
level of the mRNA transcribed from the hSOD1
E77X transgene
was 21.3+2.5% of the hwtSOD1 transgene (Fig. 1E),
suggesting that 80% of hSOD1
E77X mRNA was eliminated,
if assuming that both transgenes were equally trans-
fected, reverse transcribed and their mRNA was equally
PCR-ampliﬁed. These results support the notion that mRNA
carrying hSOD1
E77X is committed to NMD. It is currently
known that the NMD pathway is translation-dependent and
inhibition of translation of mRNA with PTC will inhibit its
NMD (16,17). To unequivocally prove that hSOD1
E77X
mRNA is degraded by this NMD pathway, we examined
the mRNA ratio of hSOD1
E77X to hwtSOD1 by treating the
transfected cells with cycloheximide. After 6 h treatment
with cycloheximide, we found that the mRNA level of the
hSOD1
E77X was increased to 63.0+3.2% of hwtSOD1
mRNA (Fig. 1E). These observations were corroborated
using another cell line, NSC34, which is derived from
mouse neural hybrid cells that exhibit some properties of
motor neurons. We found that the mRNA level of the
hSOD1
E77X was 13.4+4.8% of the hwtSOD1 mRNA in the
group without cycloheximide treatment, and increased to
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imide (Fig. 1E). We further veriﬁed these observations by
sequencing analysis of SOD1 cDNA clones (Supplementary
Material, Fig. S1).
In addition to hSOD1
E77X that has a PTC in exon 3, we also
analyzed the transgene hSOD1
K91X that has a PTC in exon 4.
We observed that 80% of hSOD1
K91X mRNA was decayed
and that inhibition of protein translation by cycloheximide
signiﬁcantly suppressed such decay in both NIH/3T3 and
NSC34 cells (Supplementary Material, Fig. S2), suggesting
that SOD1 mRNA containing a PTC in exon 4 is also com-
mitted to NMD. Thus, our data have provided multiple lines
of evidence that hSOD1
E77X and hSOD1
K91X mRNAs are
degraded by NMD. This mechanism may also underlie degra-
dation of other mutant SOD1 mRNAs containing a PTC in
exons 1–4, the non-terminal exons of SOD1,a sN M D
appears to be a universal mechanism of the cellular defense
against the potentially deleterious effects of truncated proteins
(16). This notion may reﬂect the current observation that
there is no PTC mutation identiﬁed in any exon other than
Figure 1. NMD underlying removal of mutant SOD1 mRNA with PTCs in exons 3 and 4. (A) Southern blot showing that multiple copies of hSOD1
E77X or
hSOD1
K91X transgene were integrated into mouse genome in the transgenic mice. Lane 2, human genomic DNA with two copies of SOD1 gene as a
control; lanes 1 and 3–7, DNA from transgenic mice harboring transgene hSOD1
E77X; lanes 8–10, DNA from transgenic mice harboring transgene hSOD1
K91X.
(B) The northern blot analysis of SOD1
E77X and SOD1
K91X transgenic mouse lines compared with established ALS mouse models of mutant SOD1. (Top panel)
mRNA expression of human SOD1 transgenes detected by human SOD1-speciﬁc probe. (Low panel) mRNA expression of mouse endogenous SOD1 detected by
mouse SOD1-speciﬁc probe as an internal control. Lane 1, SOD1
G93A transgenic mice that develop disease around 100 days. Lane 2, wild-type mouse (non-
transgenic) as a control. Lane 3, SOD1
L126Z transgenic mice that develop disease around 350 days. Lanes 4–7, SOD1
E77X transgenic mice. Lane 8,
SOD1
K91X transgenic mice. (C) Representative sequence electropherograms showing NMD of SOD1
E77X. Plasmid DNA containing cDNA of SOD1 with
SOD1
E77X mutation was mixed with plasmid containing wild-type cDNA of SOD1 at 10 different ratios by amount, i.e. from 0.1 to 1.0 (mutant/wild-type).
Mixed DNA samples were used as templates for PCR-sequencing. The relative ratio of the peak height (T/G) was established by measuring the individual
peak heights representing SOD1
E77X (T) and wtSOD1 (G). The known molecular ratios (0.1–1.0) of the mutant/wild-type are labeled on the top of the sequence
electropherograms of the sub-panels (A–j). Sub-panel (k) shows a sequence electropherogram of a stop codon (TAA) at codon 77, and (l) shows wtSOD1 at
codon 77 when a single type of DNA was used. Sub-panels (m and n) show the sequence electropherograms of RT-PCR product of human SOD1 from
NIH/3T3 cells transfected with equal molar ratio of SOD1
E77X/wtSOD1 plasmids; CT, cycloheximide-treated; NT, not treated with cycloheximide. Sub-panels
(o) and (p) show the sequence electropherograms of RT–PCR product of human SOD1 from another cell line (NSC34) transfected with equal molar ratio of
SOD1E77X/wtSOD1 plasmids. (D) A standard curve showing ratios of peak height (T/G) against known molecular ratios (SOD1
E77X/wtSOD1). Cyc- (þ),
cycloheximide-treated; Cyc- (2), not treated with cycloheximide. (E) Relative steady-state mRNA levels of SOD1
E77X in cell lines of NIH/3T3 and NSC34
compared with wtSOD1. Approximately 80% of mRNA transcribed from human SOD1
E77X was eliminated, and inhibition of translation by cycloheximide sig-
niﬁcantly suppressed such elimination in both NIH/3T3 and NSC34 cell lines (Student’s t-test, P , 0.001).
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codons have been reported. Since NMD may degrade the
SOD1 mRNA with PTC in exons other than exon 5, leading
to a signiﬁcantly reduced protein amount, therefore, an insufﬁ-
cient amount of the mutant protein may not be able to cause the
disease, even if a C-terminal truncated SOD1 polypeptide has
ALS-associated toxicity.
mRNA with a PTC in the last fused exon escaping NMD
Since SOD1-mediated ALS in transgenic mice is dosage-
dependent (3,18,19), and NMD affects 80% of the SOD1
mRNA with a PTC, thus preventing high expression of the
mutant SOD1, it becomes a technical challenge for deﬁning
the ALS-associated polypeptide or domain further upstream
in SOD1. To overcome this difﬁculty, we designed an exon-
fusion approach. Based on the current understanding of
NMD, if intron 4, the last intron of SOD1 is deleted and the
last two exons are fused together to become the last exon,
then any mRNA with a PTC in exon 4 should be able to
escape NMD. To test this strategy, we deleted the 1.1 kb
intron 4, so that exons 4 and 5 were fused together as the
last exon. Previous studies suggest that two out of four
cysteines in SOD1 are predominantly involved in SOD1
aggregation in vivo; one of which is Cys146 (5). The other
cysteine remains undeﬁned. Since our initially tested trans-
genes E77X and K91X do not include Cys111, which may
play an important role in ALS pathogenesis, we tested a trans-
gene SOD1
T116X that includes all three untested cysteines
(Cys6, Cys57 and Cys111). This PTC was located in the pre-
vious exon 4 and now in the last fused exon (hSOD1
T116X). We
ﬁrst tested this transgene in cell culture models, and found that
the mRNA levels of hSOD1
T116X were about half of that of
hwtSOD1 in both cellular models (Fig. 2A and B). Since
intron 4 may contain some transcription regulation elements,
the reduction of hSOD1
T116X mRNA may not be due to
NMD, but due to reduced transcription. To test this possibility,
we analyzed the mRNA levels of hSOD1
T116X from the
cycloheximide-treated groups. Our data demonstrated that
inhibition of protein translation did not signiﬁcantly alter the
levels of hSOD1
T116X mRNA (Fig. 2A and B). These
observations were further corroborated by sequencing analysis
of the recombinant clones (Supplementary Material, Fig. S1).
The cycloheximide treatment did not signiﬁcantly increase
the steady-state levels of hSOD1
T116X mRNA, supporting
the idea that the reduction of hSOD1
T116X mRNA is not due
to NMD but most likely due to reduced transcription and/or
other mechanisms.
Development of ALS-like phenotype in transgenic mice
overexpressing HSOD1
T116X
Since the hSOD1
T116X transgene yielded approximately half of
thesteady-statemRNAlevelcomparedwiththehwtSOD1trans-
gene, transgenic mice overexpressing hSOD1
T116X may
develop ALS phenotype if truncated protein hSOD1
T116X still
has ALS-associated toxicity, and if its expression is high
enough. To test this possibility, we developed transgenic mice
overexpressing hSOD1
T116X. The hSOD1
T116X transgenic
mice had relatively lower mRNA expression from the
Figure 2. Escape of NMD via exon-fusion approach. (A) A standard curve
showing ratios of peak height (T/A) against known molecular ratios
(hSOD1
T116X/hwtSOD1). (B) Relative steady-state mRNA levels of
hSOD1
T116X in cell lines of NIH/3T3 and NSC34 represent approximately
half of hwtSOD1 mRNA. However, inhibition of translation by cycloheximide
does not affect the steady-state mRNA level of hSOD1
T116X in either NIH/3T3
or NSC34 cell line (Student’s t-test, P . 0.5). (C) The northern blot analysis
of hSOD1
T116X transgenic mouse lines compared to established ALS mouse
models of mutant SOD1. Lane 1, SOD1
G93A mice that develop disease by
100 days. Lane 2, SOD1
A4V low expressor line that never develops disease,
even when crossed with hwtSOD1 transgenic mice. Lane 3, SOD1
A4V high
expressor line that do not develop disease alone. However, they will
develop disease by 8 months when crossed with the hwtSOD1 transgenic
mice (6). Lane 4, hwtSOD1 transgenic mice that do not develop disease (3).
Lane 5, SOD1
L126Z high expressor line that develops disease by 12 months.
They will develop disease by 6 months when crossed with hwtSOD1 transgenic
mice (5). Lane 6, SOD1
L126Z low expressor line that never develops disease
even when crossed with hwtSOD1 transgenic mice. Lane 7, SOD1
T1116X high
expressor line that develops disease by 10 months in the homozygous state
(double dose). They will develop disease by 13–18 months when crossed
with hwtSOD1 transgenic mice. Lanes 8 and 9, SOD1
T1116X low expressor
lines that do not develop disease in their life time.
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T116X transgene when compared with our previously
established ALS mouse models overexpressing other SOD1
mutants (Fig. 2C). The hemizygous mice did not develop an
ALS-like phenotype in their life time. To increase the
hSOD1
T116X expression, we interbred the hSOD1
T116X hemizy-
gous mice. We obtained onepossiblehSOD1
T116X homozygous
mouse out of six transgene-positive pups from a single inter-
breeding (Supplementary Material, Fig. S3). This mouse devel-
oped ALS-like phenotype that was very similar to disease
phenotypeobservedintheothertransgenicmiceoverexpressing
SOD1
G93A, SOD1
A4V or SOD1
L126Z, resulting in premature
death by 10 months with a disease duration of 2 weeks.
Since the integration of the transgene into the mouse
genome may interrupt a gene function, loss of such a function
in homozygotes may contribute to ALS-like phenotype. To
exclude this possibility and to further verify that
hSOD1
T116X is toxic, we generated hSOD1
T116X/hwtSOD1
double transgenic mice. We have previously demonstrated
that hwtSOD1 could convert the unaffected phenotype in
SOD1
A4V mice to ALS-like phenotype in SOD1
A4V/hwtSOD1
double transgenic mice in a mutant dose-dependant manner
(5). This phenomenon is associated with the conversion of
the hwtSOD1 to insoluble aggregates through intermolecular
disulﬁde bonds (5,6). We obtained ﬁve double transgenic
mice (hSOD1
T116X/hwtSOD1) and these mice developed
ALS-like phenotype and died of the disease by 13–18
months, with disease duration of 2–3 weeks (Fig. 3A, and
Supplementary Material, Fig. S4). Over half of the motor
neurons in the anterior horns of lumbar segment were lost
(Fig. 3B). Similar to ALS mouse models overexpressing
other SOD1 mutants, immuno-reactive SOD1 aggregates
and astrocytosis were apparent in these affected mice
(Fig. 3C–E). Consistent with our previous observation (5),
hwtSOD1 was shown to be recruited into SOD1 aggregates
using an antibody (c-SOD1) against the C-terminal
polypeptide (5) that is deleted in truncated hSOD1
T116X
protein (Fig. 4). These aggregates were largely present in
neuritic processes and some surviving large neurons
(Fig. 4A and B). These aggregates also included ubiquitin
(Fig.4C–E) and were prominent in anterior root axons
(Fig. 4F–H).
DISCUSSION
The toxic properties of mutant SOD1 has been examined using
various conditions in vitro and in vivo (7,20–26). Different
approaches have various advantages and drawbacks. Com-
pared with an in vivo approach, the in vitro approach is less
time-consuming and many inﬂuential factors may be con-
trolled. The in vitro approach has provided signiﬁcant infor-
mation for understanding the biophysical and biochemical
properties of SOD1 mutants. However, because ALS is a clini-
cal diagnosis of a complex disease process and many different
cell types may be involved in the pathogenesis (19,27–33), the
disease process may not be adequately modeled using in vitro
systems. Thus, whether a speciﬁc property identiﬁed in vitro
has signiﬁcant pertinence to the pathogenesis of ALS
remains to be further addressed. A challenging example is
that all four cysteines in SOD1 have been found to be reactive
in the intermolecular crosslinking by disulﬁde bonds, leading
to SOD1 aggregation under oxidative conditions in vitro (6).
However, it seems that only two of the four cysteines signiﬁ-
cantly contributed to SOD1 aggregation by this crosslinking in
mouse models during the disease process (5,6). Alternatively,
the use of chick embryo spinal cords has been shown to be a
sensitive tool to analyze SOD1 aggregates and neural cell
death (34), but it is yet to be determined if neural cells in an
embryonic stage share the same properties as adult neurons.
Furthermore, axonal degeneration rather than neuronal cell
death per se may be the primary pathology that triggers the
ALS symptoms (35,36). Using SOD1 cDNA transgene under
the control of other gene promoters is another alternative
choice to characterize the SOD1 toxicity in a mouse model
Figure 3. Development of ALS-like phenotype and pathology in the
hSOD1
T116X transgenic mice. (A) hSOD1
T116X/hwtSOD1 double transgenic
mice showing ALS-like phenotype, including motor impairment, paralysis,
muscle atrophy (especially in the hind legs) and loss 30% of body weight
by the end-stage. (B) A representative section showing severe loss of motor
neurons in the anterior horn of lumbar spinal cord. Immunohistochemistry
using an antibody against ChAT shows a ChAT-positive motor neuron
(arrow). An average number of motor neurons in the L1 to L3 segments in
an affected mouse that we analyzed in detail was 6.4+2.6 per anterior
horn, compared to 14.6+4.3 per anterior horn in a control (Student’s t-test,
P , 0.001); bar, 100 mm. (C–E) Confocal microscopy showing SOD1 aggre-
gates (green in C) and astrocytosis (D) in spinal cord sections of affected mice.
Astrocytes are shown as glial ﬁbrillary acidic protein-positive cells in red (D).
No apparent SOD1 aggregates have been observed in astrocytes (overlay in E).
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the different gene expression proﬁles driven by other promo-
ters have signiﬁcant inﬂuence on the pathogenesis of the
disease. The genomic SOD1 transgenes may have authentic
expression proﬁles, but NMD prevents further characterization
of the mutants with PTCs upstream of exon 5.
NMD is an RNA surveillance pathway that destroys aber-
rant mRNAs containing PTCs, so that cells can be protected
from the deleterious effects of the truncated proteins (16).
We used SOD1 promoter to drive SOD1 cDNA expression,
so that NMD could be bypassed. However, this approach did
not yield enough SOD1 expression (data not shown),
suggesting that SOD1 introns have important transcriptional
regulatory elements required for high expression. Therefore,
we deleted the last intron. Although deletion of the last
intron resulted in reduction of approximately half of the
SOD1 mRNA in cell culture, we speculated that such a
reduction in expression may still be sufﬁcient to cause
ALS-like phenotype in homozygous mice if the truncated
SOD1 has ALS-associated toxicity. Development of the
ALS-like phenotype and pathology in the SOD1
T116X homozy-
gous and SOD1
T116X/hwtSOD1 mice demonstrates that an
N-terminus polypeptide of only 115 amino acid has sufﬁcient
toxicity to cause ALS. This is the shortest ALS-associated
SOD1 molecule currently deﬁned in ALS mouse models (7).
Although we did not narrow down the toxic fragment substan-
tially, our data have provided proof-of-principle evidence that
the exon-fusion approach has promising potential for further
deﬁning the toxic SOD1 fragment that is crucial for triggering
ALS and thus as a molecular target for designing rational
therapy. This approach may also have general applications
to molecular dissection of the disease-associated toxicities of
other proteins, which are encoded by genes with multiple
exons, with a ‘gain of function’ mechanism.
Figure 4. Recruitment of wtSOD1 into aggregates in spinal cord and anterior root axons of hSOD1
T116X/hwtSOD1 double transgenic mice. (A and B) Immu-
nohistochemical staining with an antibody against the last 28 amino acid of SOD1 (c-SOD1) (5) showed a large number of wtSOD1 aggregates in the spinal cord
sections of the affected mice (A and B). These aggregates were predominantly present in neuritic processes (arrows). Some wtSOD1 aggregates were found in
surviving large neurons (arrowhead in B). Some neuritic processes with wtSOD1 aggregates were apparently swollen (large arrows in A and B). (C–E) Immuno-
reactive SOD1 aggregates containing ubiquitin. Confocal microscopy showing c-SOD1-positive aggregates (green in C) and ubiquitin (red in D) in spinal cord
sections of affected mice. Signals from SOD1 and ubiquitin largely overlapped (overlay in E). (F–H) Prominent SOD1 aggregates in anterior root axons. Con-
focal microscopy showing c-SOD1-positive aggregates (green in F) in anterior root axons with neuroﬁlament medium chain staining (red in G) in the spinal cord
sections of affected mice. Compared with axons in the neighboring spinal cord, the anterior root axons had more prominent SOD1 aggregates. A representative
anterior root axon without apparent SOD1 aggregates is shown by a large arrow, and a representative anterior root axon with SOD1 aggregates is shown by a
small arrow. Most of the anterior root axons showed prominent SOD1 aggregates (overlay in E).
Human Molecular Genetics, 2008, Vol. 17, No. 15 2315Truncated SOD1 is extremely unstable in soluble fraction of
the cells. Previous studies demonstrated that truncated
SOD1
L126Z was present as insoluble aggregates and was vir-
tually undetectable in the soluble fraction in the affected
ALS mice (5,14,15), suggesting that the insoluble SOD1
aggregates, rather than the soluble form of SOD1 are causally
associated with the disease. We have previously shown that
wtSOD1 can be recruited into SOD1 aggregates when
ALS-associated mutant SOD1 is present; this recruitment
can either exacerbate the disease in SOD1
G93A and
SOD1
L126Z mice or convert the phenotype from unaffected
to affected status in SOD1
A4V mice (5). By crossbreeding
the unaffected SOD1
T116X hemizygous mice with hwtSOD1
mice, we have showed in the present study that wtSOD1 can
also convert SOD1
T116X mice from an unaffected to affected
status. This phenotypic transition is related to conversion of
wtSOD1 into aggregates, as shown by antibody c-SOD1 in
immunohistochemistry and confocal microscopy. Thus, our
data suggest that recruitment of wtSOD1 into aggregates,
thereby exacerbating the disease or converting to the disease
status, may be a common phenomenon. This phenomenon,
in turn, provides further support to the hypothesis that SOD1
aggregates are ALS-associated toxic species, regardless of
whether they are composed of mutant or wild-type SOD1 (5).
The current consensus regarding the mechanism of how
mutant SOD1 causes ALS is that mutant SOD1 becomes
toxic through gain of either a normal function or a novel
toxic property. The additive effect of wtSOD1 aggregates on
the mouse phenotype supports a hypothesis that wtSOD1 per
se also has an endogenous ALS-associated toxicity; this
endogenous toxicity is enhanced by mutations; this endogen-
ous toxicity is likely derived from the propensity to SOD1
aggregation. This hypothesis is supported by the observations
that (i) overexpression of ALS-associated SOD1 mutants in
transgenic mice over a certain level causes ALS-like pheno-
type, but overexpression of wtSOD1 at a comparable level
does not lead to ALS-like phenotype (3,18); (ii) SOD1 aggre-
gation seems a common pathological feature in ALS mouse
models (5,7); (iii) recruitment of wtSOD1 into the aggregates
exacerbates the disease in SOD1
G93A and SOD1L126Z mice or
converts the phenotype from unaffected to affected status in
SOD1
A4V (5) and the newly developed SOD1
T116X mice;
(iv) both wtSOD1 and ALS-associated SOD1 mutants have
the propensity to aggregation in vitro, with wtSOD1 having
a lower propensity to aggregation than the ALS-associated
mutant SOD1 (6); (v) wtSOD1 can form heterodimers/
heteromultimers with mutant SOD1, and homodimers and
homomultimers alone through intermolecular disulﬁde bonds
in the SOD1
L126Z/hwtSOD1 double transgenic mice with
exacerbated disease (5,6).
During SOD1 aggregation in the disease process, two out of
four cysteines are predominantly oxidized (5). The preferential
involvement of cysteines in SOD1 suggests that the amino
acid sequence ﬂanking cysteines and the overall conformation
of the polypeptide play an important role in the determination
of the crosslinking reactivity of individual cysteines in vivo.
Since a truncated SOD1 polypeptide with only one reactive
cysteine is sufﬁcient to form SOD1 dimers and cause the
disease (5), a minimum N-terminal SOD1 polypeptide that is
essential for ALS-associated toxicity may be further deﬁned.
Meanwhile, it is also possible that another SOD1 polypeptide
of the C-terminus with a reactive Cys146 is able to form SOD1
dimers and cause ALS. Further investigation of these possibi-
lities in mouse models may provide important clues for under-
standing the molecular mechanism of SOD1 aggregation
in vivo and the pathogenesis of mutant SOD1-mediated ALS
in humans. The observations that no PTC mutation has been
identiﬁed in any exon other than exon 5 of SOD1 in ALS
patients, and that SOD1
T116X mice develop ALS-like pheno-
type and pathology may provide a vivid example that NMD
is an important mechanism to protect cells from the deleter-
ious effects of a truncated protein (16).
MATERIALS AND METHODS
Construction of human SOD1 transgenes
Three transgenes (hSOD1
E77X, hSOD1
K91X and hSOD1
T116X)
were constructed. A 7 kb PvuII/BamHI fragment containing
exons 2, 3 and 4 and mutant exon 5 in a pBluescript
plasmid vector was used as a template for PCR to introduce
PTCs (E77X or K91X) into exon 3 or 4 by site-directed muta-
genesis (Stratagene, La Jolla, CA, USA). Primer hSOD1-
K77Xf (50-ggtgggccaaaggattaagagaggcatgttg-30) was used to
introduce a PTC in exon 3, and primer hSOD1-K91X
(50-caatgtgactgctgactaagatggtgtggccga-30) in exon 4, respect-
ively. The entire construct was assembled by ligation of a
4.6 kb EcoRI/PvuII fragment containing exon 1 and the 7 kb
PvuII/BamHI fragment containing the E77X or K91X
mutation into the pBluescript plasmid vector. For construction
of transgene SOD1
T116X, intron 4 was deleted with primer
hSOD1
delI4 (50-cattggccgcacactgcatgaaaaagcagat-30) and a
PTC was introduced into exon 4 at codon 116 with primer
hSOD1-T116X
delI4 (50-tgcatcattggccgctaacat gaaaaagcagat
-30). Deletion of the 1.1 kb intron 4 resulted in a fusion of
exons 4 and 5. Then the 5.9 kb PvuII/BamHI fragment
without intron 4 was ligated with the 4.6 kb EcoRI/PvuII
fragment containing exon 1 to assemble into transgene
hSOD1
T116X. The plasmids containing these transgenes were
propagated in Escherichia coli XL 1 blue. The DNA sequence
of the transgenes was veriﬁed by sequencing.
Cell culture and transfections
NIH/3T3 and NSC 34 cells, both derived from mouse cell
lines, were grown in Dulbecco’s modiﬁed Eagle’s medium
in 6-well plates. Transient transfections were performed
using SuperFect Transfection reagent (Qiagen, Valencia,
CA, USA). Plasmid DNA containing the hwtSOD1 gene was
mixed with plasmid DNA containing a mutant SOD1 gene
(hSOD1
E77X,o rhSOD1
K91X) in equal amounts (2 mg each).
The hwtSOD1 plasmid was mixed with plasmid containing
hSOD1
T116X at a ratio of 1:0.924 (2 and 1.85 mg, respect-
ively). This ratio was calculated based on the different mole-
cular weight of the plasmids, so that the molar concentration
of the hwtSOD1 and hSOD1
T116X during transfections
would remain the same. The transfected cells in the 6-well
plates were divided into two groups. The cells in the lower
three wells were treated with cycloheximide (200 mm) and
the cells in the top three wells were not cycloheximide-treated.
2316 Human Molecular Genetics, 2008, Vol. 17, No. 15In the cycloheximide-treated group, the transfected cells were
cultured for 16 h and then cycloheximide was added. Cells
were harvested 6 h later. In the non-cycloheximide-treated
group, the transfected cells were harvested without further
cycloheximide treatment. Each treatment was triplicated.
RNA isolation, reverse transcription–PCR (RT–PCR)
and sequencing
Total RNA was prepared using a Purescript RNA Puriﬁcation
System (Gentra, Minneapolis, MN, USA). One microgram of
RNA was used for reverse transcription using avian myelo-
blastosis virus reverse transcriptase and a human SOD1-
speciﬁc primer (hSOD130R: 50-ctacagctagcaggataa
cagatgag-30). The synthesized ﬁrst-strand cDNA fragments
were PCR-ampliﬁed using two human SOD1-speciﬁc
primers with an anchored EcoRIo rXhoI restriction site,
respectively (SOD1EcoRIf: 50-cagtgaattcgaccagtgaaggtgtggg
gaagc-30, SOD1XhoIr: 50-gatcctcgagccacctttgcccaagtcatctgc-
30). The RT–PCR product was agarose gel puriﬁed using
QIAGEN Gel Extraction Kit (QIAGEN Science, MD, USA).
An aliquot of the PCR product was directly sequenced using
PCR primers. For subcloing, the rest of the PCR product
was digested with EcoRI/XhoI and agarose-gel puriﬁed.
Subcloning and sequencing
The restriction enzyme-digested and puriﬁed SOD1 cDNA
fragments were subcloned into the EcoRI and XhoI sites of
pBluescript plasmid vector. Bacterial clones with recombinant
plasmid were randomly selected and cultured. Individual
plasmid DNA was extracted and sequenced using a CEQ
8000 GeXP sequencer (Beckman Coulter Inc., Fullerton,
CA, USA).
Dosage analysis
Plasmid DNA containing an EcoRI/XhoI cDNA fragment with
a mutation (either E77X, K91X or T116X) was mixed with
plasmid containing a wild-type EcoRI/XhoI cDNA fragment
at 10 different ratios by amount, i.e. from 0.1 to 1.0
(mutant/wild-type). Mixed DNA samples were used as tem-
plates for PCR using the same protocol as that used in RT–
PCR, and the PCR products were sequenced. The ratio of
the peak height was established by measuring the individual
peak height (T/G in 77X or T/A in 116X) at these 10 points
with known plasmid DNA ratio (mutant/wild-type, 0.1–1.0).
Triplicate experiments were performed and the mean ratios
were taken to draw a standard curve and equation using Micro-
soft Excel. Similarly, the mean ratios (mutant/wild-type) of
the peak height of the RT–PCR products were converted to
percentage based on the standard curves and equations using
wild-type SOD1 as 1 (100%).
Development of transgenic mice overexpressing mutant
SOD1
The 11.6 kb EcoRI/BamHI fragment containing the E77X or
K91X mutation and the 10.5 kb EcoRI/BamHI fragment con-
taining the T116X mutation were released by EcoRI/BamHI
double digestion, agarose gel-puriﬁed and used for microinjec-
tion into fertilized eggs derived from a zygote of a C57BL/6  
SJL cross. Transgenic mice were initially identiﬁed by PCR by
using human SOD1-speciﬁc primers at the 30-UTR of the
SOD1 gene (HSOD1-30 forward, 50-ccaataaa
cattcccttggatg-30; HSOD1-30 reverse, 50-caggatacatttctacagcta
g-30) and subsequently conﬁrmed by southern blot. Potential
homozygous mice were analyzed by southern blot. Onset of
disease phenotype in mice is deﬁned by showing more than
one of the following signs: (i) ﬁne tremor at one or more
toes when suspended in the air; (ii) reduced spontaneous
movement; (iii) failure to gain weight or loss of weight;
(iv) poor grooming; (v) muscle weakness; and (vi) partial
paralysis. End-stage of the disease is deﬁned as when a
mouse is paralyzed and cannot right by itself in 30 s after it
is laid on one side. Animal-use protocols have been approved
by the Institutional Animal Care and Use Committee of North-
western University for this project.
Southern and northern blot analysis
For southern blot, ﬁve micrograms of mouse genomic DNA
were digested with PstI to completion, separated on a 0.8%
agarose gel, and transferred to a nylon membrane. The mem-
brane was dried for 2 h at 808C. A genomic DNA fragment of
600 bp in size from intron 1 of human SOD1 gene was used as
a probe. This fragment was PCR-ampliﬁed using human
SOD1-speciﬁc primers (hSOD1-spF: 50-gttctaggtcatgattggg
ctg-30; hSOD1-spR: 50-caccagttggtaacttcactaag-30). The probe
was labeled with dGTP-
32P by PCR. Hybridization was
carried out using a hybridization solution (0.125 M
Na2HPO3/0.25 M NaCl/7% SDS/1 mM EDTA/10% PEG) at
658C for 18 h. The hybridized membrane was washed with
2X SSC/0.1% SDS for 30 min and 0.5X SSC/0.1% SDS for
30 min and then exposed to X-ray ﬁlm. For northern blot, 15
micrograms of total RNA isolated from brain were separated
on a 1% agarose gel containing formaldehyde, and transferred
to a nylon membrane. The membrane was dried for 2 h at
808C. For detection of human SOD1 transgene expression, a
human SOD1-speciﬁc probe was used. This probe, 78 bp in
size from the 30 untranslated region of human SOD1, was
PCR ampliﬁed using two primers (hSOD1-30F:
50-ccaataaacattcccttggatgt-30; hSOD1-30R: 50-caggatacatt tcta-
cagctagc 30). For the detection of mouse endogenous SOD1
expression, a mouse SOD1-speciﬁc probe was used. This
probe, 94 bp in size from the 30 untranslated region of
mouse SOD1, was PCR ampliﬁed using two primers
(mSOD1-30F: 50-gattgcgcagtaaacattccctgt-30; mSOD1-30R:
50-cacagttacaactcttcagattac-30).
Histopathological analysis
Mice deeply anesthetized with an intra-peritoneal injection of
pentobarbarbital (0.15 mg/g) were sacriﬁced by total body per-
fusion with 60 ml of fresh saline followed by freshly prepared
4% paraformaldehyde in PBS. Brain and spinal cord were
removed, postﬁxed in the same ﬁxative, and embedded in par-
afﬁn. The sections were made at 6 mm for routine pathological
examination and immunohistochemistry. For immunohisto-
chemistry, the sections were deparafﬁnized and rehydrated
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in xylene, three times for 5 min in 100% ethanol, three times
for 3 min in 95% ethanol, once for 5 min each in 75% ethanol,
50% ethanol, deionized water and PBS, respectively. The anti-
gens in the sections were retrieved using a decloaking chamber
(Biocare Medical, Walnut Creek, CA, USA) with a retrieval
solution (10 mM citrate acid, pH 6.0) for 20 min. The sections
were cooled to room temperature for 30 min and rinsed with
deionized water for 5 min. Possible intrinsic endogenous per-
oxidase activities were blocked with 2% hydrogen peroxide.
Non-speciﬁc background was blocked with PBS/1% BSA for
20 min at room temperature. The speciﬁc primary antibody
of interest (such as f-SOD1) was applied to the slides and incu-
bated at room temperature for 1 h. After rinsing the slides, a
biotinylated secondary antibody in PBS was applied, and the
slides were incubated at room temperature for 30 min. After
removing the excess secondary antibody, a peroxidase-
conjugated streptavidin (BioGenex, San Ramon, CA, USA)
was applied, and the slides were incubated for 30 min at
room temperature. After rinsing, positive signals were devel-
oped by incubating the slides with 3-amino-9-ethylcarbazole
chromogen. The slides were counterstained with appropriate
counterstaining reagents and sealed with Aqua Poly/Mount
(Polyscience, Warrington, PA, USA). The slides were exami-
ned and photographed under a light microscope.
Quantiﬁcation of anterior horn motor neurons was per-
formed on 9 mm transverse sections of lumbar spinal cord
from L1 to L3, the lumbar enlargement in mice. In every
third section, at least 20 sections total from each animal was
immuno-stained with antibody against choline acetyltransfer-
ase (ChAT) (Chemicon International, Temecula, CA, USA).
The areas of the anterior horn where motor neurons were
counted included laminae VII, VIII and IX. Cells that met
the following criteria in this area were counted as a motor
neuron: (i) ChAT positive; (ii) cell body diameter over
15 mm; (iii) with a clearly deﬁned cytoplasm containing
nucleus and prominent nucleolus.
Confocal microscopy
Sections were prepared by using the same protocols as
described in the Histopathological Analysis. After antigen
retrieval, the sections were then blocked in a PBS solution
containing 1% BSA for 1 h. Primary antibodies raised in
different hosts (such as rabbit anti-SOD1, mouse anti-GFAP)
were then applied with appropriate dilutions for 1 h followed
by at least four 10 min wash steps before exposure to the sec-
ondary antibody solution (Pierce goat anti-mouse IgG conju-
gated with rhodamine and Chemicon goat anti-rabbit IgG
conjugated with FITC at appropriate dilution). This was fol-
lowed by four additional 10 min wash steps. The specimens
were mounted in Antifade mounting media (Molecular
Probes). Specimens were examined by using an LSM 510
META Laser Scanning Confocal Microscope with its multi-
tracking setting. The same pinhole diameter was used to
acquire each channel.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
ACKNOWLEDGEMENTS
We thank Janice Caliendo for proofreading this manuscript.
Conﬂict of Interest statement. None declared.
FUNDING
The authors acknowledge the support from the National Insti-
tutes of Health Grants NS40308 (H.-X.D.), NS050641 and
NS046535 (T.S.); the Les Turner ALS Foundation, the
National Organization for Rare Disorders, the Vena
E. Schaff ALS Research Fund, a Harold Post Research Profes-
sorship, the Herbert and Florence C. Wenske Foundation, the
Ralph and Marian Falk Medical Research Trust, an Abbott
Labs Duane and Susan Burnham Professorship, and the
David C. Asselin MD Memorial Fund (T.S.). Funding to pay
the Open Access publication charges for this article was
provided by the Les Turner ALS Foundation.
AUTHOR CONTRIBUTIONS
H.-X.D. and T.S. designed the research. H.-X.D., H.J., R.F.,
H.Z., Y.S. and M.H. developed the transgenic mice and per-
formed genetic analysis; H.-X.D., H.Z., E.L., M.C.D.C. and
T.S. did pathological analysis; H.-X.D. and T.S. analyzed
data and wrote the paper.
REFERENCES
1. Rosen, D.R., Siddique, T., Patterson, D., Figlewicz, D.A., Sapp, P.,
Hentati, A., Donaldson, D., Goto, J., O’Regan, J.P., Deng, H.X. et al.
(1993) Mutations in Cu/Zn superoxide dismutase gene are associated with
familial amyotrophic lateral sclerosis. Nature, 362, 59–62.
2. Deng, H.X., Hentati, A., Tainer, J.A., Iqbal, Z., Cayabyab, A., Hung,
W.Y., Getzoff, E.D., Hu, P., Herzfeldt, B., Roos, R.P. et al. (1993)
Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide
dismutase. Science, 261, 1047–1051.
3. Gurney, M.E., Pu, H., Chiu, A.Y., Dal Canto, M.C., Polchow, C.Y.,
Alexander, D.D., Caliendo, J., Hentati, A., Kwon, Y.W., Deng, H.X. et al.
(1994) Motor neuron degeneration in mice that express a human Cu,Zn
superoxide dismutase mutation. Science, 264, 1772–1775.
4. Reaume, A.G., Elliott, J.L., Hoffman, E.K., Kowall, N.W., Ferrante, R.J.,
Siwek, D.F., Wilcox, H.M., Flood, D.G., Beal, M.F., Brown, R.H., Jr et al.
(1996) Motor neurons in Cu/Zn superoxide dismutase-deﬁcient mice
develop normally but exhibit enhanced cell death after axonal injury. Nat.
Genet., 13, 43–47.
5. Deng, H.X., Shi, Y., Furukawa, Y., Zhai, H., Fu, R., Liu, E., Gorrie, G.H.,
Khan, M.S., Hung, W.Y., Bigio, E.H. et al. (2006) Conversion to the
amyotrophic lateral sclerosis phenotype is associated with intermolecular
linked insoluble aggregates of SOD1 in mitochondria. Proc. Natl Acad.
Sci. USA, 103, 7142–7147.
6. Furukawa, Y., Fu, R., Deng, H.X., Siddique, T. and O’Halloran, T.V.
(2006) Disulﬁde cross-linked protein represents a signiﬁcant fraction of
ALS-associated Cu, Zn-superoxide dismutase aggregates in spinal cords
of model mice. Proc. Natl Acad. Sci. USA, 103, 7148–7153.
7. Kunst, C.B. (2004) Complex genetics of amyotrophic lateral sclerosis.
Am. J. Hum. Genet., 75, 933–947.
8. Hardy, J. and Selkoe, D.J. (2002) The amyloid hypothesis of Alzheimer’s
disease: progress and problems on the road to therapeutics. Science, 297,
353–356.
9. Supattapone, S., Bosque, P., Muramoto, T., Wille, H., Aagaard, C., Peretz,
D., Nguyen, H.O., Heinrich, C., Torchia, M., Safar, J. et al. (1999) Prion
protein of 106 residues creates an artiﬁcal transmission barrier for prion
replication in transgenic mice. Cell, 96, 869–878.
2318 Human Molecular Genetics, 2008, Vol. 17, No. 1510. Frenkel, D., Balass, M. and Solomon, B. (1998) N-terminal EFRH
sequence of Alzheimer’s beta-amyloid peptide represents the epitope of
its anti-aggregating antibodies. J. Neuroimmunol., 88, 85–90.
11. Bard, F., Cannon, C., Barbour, R., Burke, R.L., Games, D., Grajeda, H.,
Guido, T., Hu, K., Huang, J., Johnson-Wood, K. et al. (2000) Peripherally
administered antibodies against amyloid beta-peptide enter the central
nervous system and reduce pathology in a mouse model of Alzheimer
disease. Nat. Med., 6, 916–919.
12. Taylor, J.P., Hardy, J. and Fischbeck, K.H. (2002) Toxic proteins in
neurodegenerative disease. Science, 296, 1991–1995.
13. Jonsson, P.A., Ernhill, K., Andersen, P.M., Bergemalm, D., Brannstrom,
T., Gredal, O., Nilsson, P. and Marklund, S.L. (2004) Minute quantities of
misfolded mutant superoxide dismutase-1 cause amyotrophic lateral
sclerosis. Brain, 127, 73–88.
14. Wang, J., Xu, G., Li, H., Gonzales, V., Fromholt, D., Karch, C., Copeland,
N.G., Jenkins, N.A. and Borchelt, D.R. (2005) Somatodendritic
accumulation of misfolded SOD1-L126Z in motor neurons mediates
degeneration: alphaB-crystallin modulates aggregation. Hum. Mol.
Genet., 14, 2335–2347.
15. Watanabe, Y., Yasui, K., Nakano, T., Doi, K., Fukada, Y., Kitayama, M.,
Ishimoto, M., Kurihara, S., Kawashima, M., Fukuda, H. et al. (2005)
Mouse motor neuron disease caused by truncated SOD1 with or without
C-terminal modiﬁcation. Brain Res. Mol. Brain Res., 135, 12–20.
16. Maquat, L.E. (2004) Nonsense-mediated mRNA decay: splicing,
translation and mRNP dynamics. Nat. Rev. Mol. Cell Biol., 5, 89–99.
17. Pereira, F.J., do Ceu Silva, M., Picanco, I., Seixas, M.T., Ferrao, A.,
Faustino, P. and Romao, L. (2006) Human alpha2-globin
nonsense-mediated mRNA decay induced by a novel alpha-thalassaemia
frameshift mutation at codon 22. Br. J. Haematol., 133, 98–102.
18. Wong, P.C., Pardo, C.A., Borchelt, D.R., Lee, M.K., Copeland, N.G.,
Jenkins, N.A., Sisodia, S.S., Cleveland, D.W. and Price, D.L. (1995) An
adverse property of a familial ALS-linked SOD1 mutation causes motor
neuron disease characterized by vacuolar degeneration of mitochondria.
Neuron, 14, 1105–1116.
19. Bruijn, L.I., Becher, M.W., Lee, M.K., Anderson, K.L., Jenkins, N.A.,
Copeland, N.G., Sisodia, S.S., Rothstein, J.D., Borchelt, D.R., Price, D.L.
et al. (1997) ALS-linked SOD1 mutant G85R mediates damage to
astrocytes and promotes rapidly progressive disease with
SOD1-containing inclusions. Neuron, 18, 327–338.
20. Beckman, J.S., Estevez, A.G., Crow, J.P. and Barbeito, L. (2001)
Superoxide dismutase and the death of motoneurons in ALS. Trends
Neurosci., 24, S15–S20.
21. Liochev, S.I. and Fridovich, I. (2003) Mutant Cu,Zn superoxide
dismutases and familial amyotrophic lateral sclerosis: evaluation of
oxidative hypotheses. Free Radic. Biol. Med., 34, 1383–1389.
22. Bruijn, L.I., Miller, T.M. and Cleveland, D.W. (2004) Unraveling the
mechanisms involved in motor neuron degeneration in ALS. Annu. Rev.
Neurosci., 27, 723–749.
23. Manfredi, G. and Xu, Z. (2005) Mitochondrial dysfunction and its role in
motor neuron degeneration in ALS. Mitochondrion, 5, 77–87.
24. Tiwari, A. and Hayward, L.J. (2005) Mutant SOD1 instability:
implications for toxicity in amyotrophic lateral sclerosis. Neurodegener.
Dis., 2, 115–127.
25. Rakhit, R. and Chakrabartty, A. (2006) Structure, folding, and misfolding
of Cu,Zn superoxide dismutase in amyotrophic lateral sclerosis. Biochim.
Biophys. Acta, 1762, 1025–1037.
26. Culotta, V.C., Yang, M. and O’Halloran, T.V. (2006) Activation of
superoxide dismutases: putting the metal to the pedal. Biochim. Biophys.
Acta, 1763, 747–758.
27. Kato, S., Hayashi, H., Nakashima, K., Nanba, E., Kato, M., Hirano, A.,
Nakano, I., Asayama, K. and Ohama, E. (1997) Pathological
characterization of astrocytic hyaline inclusions in familial amyotrophic
lateral sclerosis. Am. J. Pathol., 151, 611–620.
28. Yoshihara, T., Ishii, T., Iwata, M. and Nomoto, M. (1998) Ultrastructural
and histochemical study of the motor end plates of the intrinsic laryngeal
muscles in amyotrophic lateral sclerosis. Ultrastruct. Pathol., 22,
121–126.
29. Cha, C.I., Kim, J.M., Shin, D.H., Kim, Y.S., Kim, J., Gurney, M.E. and
Lee, K.W. (1998) Reactive astrocytes express nitric oxide synthase in the
spinal cord of transgenic mice expressing a human Cu/Zn SOD mutation.
Neuroreport, 9, 1503–1506.
30. Rafalowska, J. and Podlecka, A. (1998) Does the pathological factor in
amyotrophic lateral sclerosis (ALS) damage also astrocytes? Folia
Neuropathol., 36, 87–93.
31. Trotti, D., Rolfs, A., Danbolt, N.C., Brown, R.H., Jr and Hediger, M.A.
(1999) SOD1 mutants linked to amyotrophic lateral sclerosis selectively
inactivate a glial glutamate transporter. Nat. Neurosci., 2, 427–433.
32. Boillee, S., Yamanaka, K., Lobsiger, C.S., Copeland, N.G., Jenkins, N.A.,
Kassiotis, G., Kollias, G. and Cleveland, D.W. (2006) Onset and
progression in inherited ALS determined by motor neurons and microglia.
Science, 312, 1389–1392.
33. Beers, D.R., Henkel, J.S., Xiao, Q., Zhao, W., Wang, J., Yen, A.A.,
Siklos, L., McKercher, S.R. and Appel, S.H. (2006) Wild-type microglia
extend survival in PU.1 knockout mice with familial amyotrophic lateral
sclerosis. Proc. Natl Acad. Sci. USA, 103, 16021–16026.
34. Ghadge, G.D., Wang, L., Sharma, K., Monti, A.L., Bindokas, V., Stevens,
F.J. and Roos, R.P. (2006) Truncated wild-type SOD1 and FALS-linked
mutant SOD1 cause neural cell death in the chick embryo spinal cord.
Neurobiol. Dis., 21, 194–205.
35. Fischer, L.R., Culver, D.G., Tennant, P., Davis, A.A., Wang, M.,
Castellano-Sanchez, A., Khan, J., Polak, M.A. and Glass, J.D. (2004)
Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and
man. Exp. Neurol., 185, 232–240.
36. Gould, T.W., Buss, R.R., Vinsant, S., Prevette, D., Sun, W., Knudson,
C.M., Milligan, C.E. and Oppenheim, R.W. (2006) Complete dissociation
of motor neuron death from motor dysfunction by Bax deletion in a mouse
model of ALS. J. Neurosci., 26, 8774–8786.
37. Wang, J., Xu, G., Slunt, H.H., Gonzales, V., Coonﬁeld, M., Fromholt, D.,
Copeland, N.G., Jenkins, N.A. and Borchelt, D.R. (2005) Coincident
thresholds of mutant protein for paralytic disease and protein aggregation
caused by restrictively expressed superoxide dismutase cDNA. Neurobiol.
Dis., 20, 943–952.
Human Molecular Genetics, 2008, Vol. 17, No. 15 2319